Rheumatoid Endothelinitis: A Novel Endothelin-1 Driven Neurovascular Phenotype Mimicking Refractory Chronic Migraine

Background: Chronic migraine is a heterogeneous disorder, yet current therapeutic protocols often apply a "one-size-fits-all" approach. A subset of patients remains refractory to standard preventative medications, including CGRP monoclonal antibodies and onabotulinumtoxinA (Botox). Hypothesis: We propose a novel disease model, Rheumatoid Endothelinitis, characterizing a phenotype suffering from systemic Endothelin-1 (ET-1) mediated microvascular dysregulation. Unlike classical migraine, this phenotype is driven by non-vesicular purinergic (ATP) signaling secondary to tissue ischemia. Methods: Through mathematical modeling of sensitization gain (G) versus ischemic input (I), and analysis of a longitudinal familial cohort, we delineate the physiological divergence between this condition and classical ME/CFS. We analyze pharmacological response patterns to identify diagnostic markers. Results: The phenotype is characterized by a specific "pharmacological fingerprint": intolerance to vasoconstrictors (triptans) and perfusion-reducing agents (beta-blockers), and non-response to vesicular release inhibitors (Botox). Conversely, interventions promoting hemodynamic shear stress (exercise), nitric oxide synthesis (e.g., Nebivolol), and neuroplastic regulation (e.g., Psilocybin) demonstrate efficacy or mechanistic rationale. Conclusion: We identify a specific endophenotype where pain is ischemic-metabolic rather than primarily neurogenic. This mandates a stratified therapeutic approach targeting the ET-1/glial axis, moving beyond standard neuromodulation to vascular restoration. The model should be viewed as a mechanistic hypothesis that unifies multiple domains—vascular, neural, autonomic, immunological—within a single ET-1–centric pathophysiology. Its strength lies in explanatory coherence and testability, but empirical validation remains the necessary next step.